A precision medicine approach to Alzheimer’s disease

By integrating information from a well-understood drug agent, a large dataset in patients with the active molecule tramiprosate, novel genetic markers and insights into the pathology of Alzheimer’s disease (AD), we have created ALZ-801, an optimized prodrug of tramiprosate.  ALZ-801 is one of the few drug candidates in advanced stages of clinical testing in AD, a pill with a favorable safety profile and the potential to modify an underlying cause of the disease.

About ALZ-801

21Sep, 2016

Alzheon to Present at Upcoming Investor Conferences

September 21st, 2016|

FRAMINGHAM, Mass., September 21, 2016 – Alzheon Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that the company will [...]

7Sep, 2016

Alzheon to Present at Upcoming Industry Conferences

September 7th, 2016|

Company Executives Selected for Scientific and Business Presentations, Including Keynote Address, about Alzheimer’s Disease and CNS Drug Development FRAMINGHAM, Mass., Sept. 7, 2016 – Alzheon Inc., a clinical-stage biopharmaceutical company focused on developing new [...]

Load More Posts

In the news

25Jul, 2016

Alzheimer’s biotech Alzheon to move once-failed drug into new PhIII

July 25th, 2016|

Tramiprosate, like so many others, could have been consigned to the scrap heap of once-promising AD meds that didn’t quite make the grade, never to be studied again. But then in stepped small Framingham, MA-based [...]

26Jan, 2016

Alzheon Highlighted as One of the “Top 20 Life Science Startups to Watch in the U.S.”

January 26th, 2016|

Alzheon is focused on developing treatments for patients with Alzheimer’s disease and other neurological and psychiatric disorders. The company’s lead clinical product candidate, ALZ-801, is an oral inhibitor of amyloid aggregation and neurotoxicity—hallmarks of [...]

Load More Posts